PEG-MGF 2mg Peptide
For in-vitro laboratory research only. Not for human or animal administration.
Batch #: VPPM2100
Get Notified When Available
This product is currently out of stock. Enter your email and we'll notify you the moment it's back.
Research Use Only
For in-vitro laboratory research by qualified professionals only. Not for human or animal administration. Not a drug, food, cosmetic or dietary supplement. Not intended to diagnose, treat, cure, mitigate or prevent any disease. Batch-specific Certificates of Analysis available for all products.
PEG-MGF 2mg: overview
What the vial contains and what the material is, stated as specifications rather than as outcomes.
PEG-MGF supplied as a lyophilized powder in a sealed single-use vial containing 2 mg of material. PEG-MGF: molecular weight 2,867 g/mol (peptide portion, before PEGylation). Released to a specification of >99% purity by HPLC. Soluble in bacteriostatic water. Supplied for in-vitro laboratory research only. Not a drug, food or supplement. Not for human or veterinary use.
Volta does not provide dosing, administration or protocol guidance for any material listed.
PEG-MGF 2mg specifications
Every field the product record holds. A field with no value is omitted rather than printed as a dash.
- Fill
- 2mg
- Form
- Lyophilized powder
- Molecular weight
- 2,867 g/mol (peptide portion, before PEGylation)
- Solubility
- Soluble in bacteriostatic water
- Shelf life
- 24 months from date of manufacture
PEG-MGF analytical verification and batch documentation
What the purity figure on this page is, who measured what, and which of the two a reader is looking at.
Specification. Every batch is released to >99% purity by HPLC. That is a threshold Volta sets, and it is a promise rather than a measurement.
Measurement. No certificate for this compound is published on the site yet. A batch-specific Certificate of Analysis is available on request, and the batch history lists the ones already published. Until one is published for this material, the figure above is the release specification and nothing on this page is a laboratory result.
Checking a certificate. The batch number printed beside the price is derived from the compound code and the vial strength; the lot number on a certificate is transcribed from the document. They are produced independently, so comparing them is a real check. How to read one is set out in the quality and testing methodology page.
For in-vitro laboratory research by qualified professionals only. Not for human or animal administration. Not a drug, food, cosmetic or dietary supplement. Not intended to diagnose, treat, cure, mitigate or prevent any disease.
Mechano-growth factor is the splice variant of IGF-1 that muscle produces in response to mechanical loading and damage, and its distinguishing feature is the E-domain, which appears to act on satellite cell proliferation through a pathway separate from the IGF-1 receptor. The unmodified peptide clears within minutes, which makes it impractical to study; PEG conjugation extends that window substantially. Because PEG chain size varies between preparations, total molecular weight is preparation-dependent and only the peptide portion is quoted here.
- Released to a >99% purity specification by HPLC
- Lyophilized powder, 2mg per vial
- Soluble in bacteriostatic water
- For laboratory research use only
Frequently Bought Together
PEG-MGF 2mg
2mg
$54 USD
Bundle & Save
$128 USD
Save $6.40 USD
$177 USD
Save $17.70 USD
$213 USD
Save $31.95 USD
$248 USD
Save $49.60 USD
Click any product above to toggle selection
Related research materials
PEG-MGF 2mg: what is in the vial
The arithmetic specific to this 2mg vial, and what a milligram of PEG-MGF costs in each strength the catalogue carries. Concentrations are stated, not recommended.
Vial contents
2 mg
Lyophilised powder, reconstituted by the buyer
Cost of material
$27 / mg USD
CA$38.50 / mg in Canadian dollars
Concentration at each diluent volume
2 mg of dry material reaches these concentrations in the volumes below. A U-100 syringe marking is 0.01 ml by definition, so the last column is a unit conversion at each concentration rather than a quantity to use.
| Diluent added | Concentration | In 0.1 ml | Per U-100 unit |
|---|---|---|---|
| 1 ml | 2 mg/ml | 200 mcg | 20 mcg |
| 2 ml | 1 mg/ml | 100 mcg | 10 mcg |
| 3 ml | 667 mcg/ml | 66.7 mcg | 6.7 mcg |
| 5 ml | 400 mcg/ml | 40 mcg | 4 mcg |
For a volume this table does not list, the reconstitution calculator takes any vial size and diluent volume.
PEG-MGF purity and identity: how the figure is measured
What >99% (HPLC) means, the masses an identity check has to land on, and the entries that make a certificate of analysis checkable rather than decorative.
Stated purity
>99% (HPLC)
Area percent of the main peak by reversed-phase HPLC
Average mass
2,867 g/mol
The figure an identity check has to land on
Identity by mass: the ions to expect
An electrospray source protonates the molecule rather than weighing it neutral, so a spectrum shows a series of charge states rather than the molecular weight itself. These are the m/z values 2,867 g/mol produces, and they are what a mass spectrum on a certificate for PEG-MGF has to match.
| Ion | Charge | Expected m/z |
|---|---|---|
| [M+H]+ | 1+ | 2,868.01 |
| [M+2H]2+ | 2+ | 1,434.51 |
A peptide this size is normally reported at its doubly and triply charged states, and the singly charged ion may not appear at usable intensity at all. A spectrum showing only one of these is not a failed identity check.
What a certificate for PEG-MGF should carry
A purity percentage on its own is not checkable. These are the entries that make one verifiable, and their absence is the most common weakness in a research-peptide certificate.
The chromatogram, not only the number
A stated area percent with no trace behind it cannot be read for the shape of the main peak or for what eluted beside it. The HPLC interpreter walks through what a trace shows.
Net peptide content, separately from gross mass
A lyophilised peptide is a salt, usually of trifluoroacetic or acetic acid, plus residual water. The vial's stated milligrams are gross; net peptide content is the fraction of that mass which is the molecule. The two differ by ten to twenty percent routinely, and only one of them is what the price is per milligram of. The net peptide content calculator converts between them.
The counterion, named
Which salt form the powder is in changes the net content and the pH the powder dissolves at. A certificate that never names it leaves both unknowable.
Water content, by a stated method
Loss on drying and Karl Fischer titration give different numbers, and a water figure with no method attached cannot be compared with anyone else's.
A laboratory and a report identifier
Without both, nothing on the document can be traced back to the laboratory that issued it. The red flag checker lists the rest.
Batch certificates are published as page images in the certificate library. The source PDFs are never served: a certificate is the most forgeable document a supplier publishes, and an editable copy carrying an accredited laboratory's letterhead is worth more to a counterfeiter than to a customer.
PEG-MGF storage and stability
Handling as the product record states it, followed by the degradation chemistry this particular sequence is and is not exposed to.
Handling
Store lyophilized peptide at -20°C in a dry, dark environment. Reconstitute in bacteriostatic water. Once reconstituted, store at 2-8°C and use within 30 days. Avoid repeated freeze-thaw cycles. Lyophilized powder is stable at room temperature for shipping and short-term storage.
A residue-level stability profile needs a primary sequence of standard amino acids. This compound's sequence carries modified or non-standard residues, so no finding is derived for it rather than one being estimated from a partial reading. The storage guide covers the general case.
PEG-MGF compared with ACE-031 and GHRP-2
Pharmacological class, half-life, evidence grade, competition status and cost per milligram, side by side.
| Compound | Class | Half-life | Evidence | WADA | Cheapest per mg |
|---|---|---|---|---|---|
| PEG-MGFthis page | Muscle & Performance | Native MGF: minutes; PEG-MGF: estimated several hours (no published human PK data) | DPreclinical | Prohibited | $272mg vial, out of stock |
| ACE-031 | Muscle Growth / Research | ~10-14 days (Fc-mediated FcRn recycling) | CEarly Human or Mixed Evidence | Prohibited | $741mg vial, out of stock |
| GHRP-2 | Growth Hormone Secretagogue | ~15–60 minutes | CPhase I–II Clinical Trials | Prohibited | $5.605mg vial |
| GHRP-6 | Growth Hormone Secretagogue | ~15–60 minutes | DPreclinical | Prohibited | $6.635mg vial |
| Ipamorelin | Growth Hormone Secretagogue | ~2 hours | DPreclinical | Prohibited | $7.205mg vial |
Evidence grades and half-lives are as recorded in the compound database, which cites its own sources on each compound page. Per-milligram prices are the cheapest strength each compound is currently listed at, in US dollars, and an out-of-stock note means that figure is not purchasable today. Cross-trial comparisons of efficacy are not comparisons: no head-to-head trial exists for most of these pairs.
PEG-MGF in Canada
Price in Canadian dollars, where the parcel ships from, and how long it takes.
Price in CAD
CA$77
The figure charged, not a converted estimate
Ships from
British Columbia
A domestic parcel, so no import clearance step
Transit
2 to 5 business days
After 1 to 2 business days of handling
Free standard shipping
Over CA$250
A bar set for this market, not converted from the US one
PEG-MGF 2mg ships from British Columbia to Canadian addresses, so the parcel never crosses a border. That removes the failure a Canadian buyer of research peptides is usually weighing: an inbound international shipment can be held for import clearance or seized, and a domestic one has no clearance step to be held at.
Shipping is quoted live against the delivery address at checkout rather than estimated here, and both the standard and express tiers show their price and transit window before a payment method is chosen. The figure the page shows is the figure the rail charges: all three settlement rails price shipping through the same functions the quote does.
The Canadian figure above is not a loose conversion. Each product's US dollar base is chosen so that the live conversion lands on the Canadian shelf price set for this market, and the result is pushed up to a whole dollar rather than left carrying cents, so one figure serves the page, the feed and every payment rail. See the shipping policy for carriers and cut-off times, and the legal position on research peptides in Canada for the regulatory picture.
PEG-MGF Mechanism of Action
Mechano-growth factor is the name given to IGF-1Ec, a splice variant of insulin-like growth factor 1 that skeletal muscle expresses in response to mechanical loading and damage. What distinguishes it from the main IGF-1 isoform is its C-terminal E-domain, a short peptide sequence produced when the propeptide is processed, and it is that E-domain peptide rather than the whole protein that is sold under the MGF name.
The E-domain is reported to act on satellite cells, the resident muscle progenitors that proliferate and fuse to repair damaged fibres. The interesting claim in this literature is that the E-domain acts through a pathway distinct from the IGF-1 receptor, which would make it a separate signal rather than simply another way of engaging IGF-1 signalling. Work on the human Ec peptide describes it as the active core of a progression growth factor with species-specific behaviour, which is a specific and unusual property.
PEGylation is a separate matter entirely. The E-domain peptide has a very short half-life, and attaching polyethylene glycol increases hydrodynamic radius, slows renal filtration and shields the molecule from proteases. That is a well-established pharmaceutical technique applied to many proteins including IGF-I itself. What is not established is what it does to this particular peptide, because no published study has examined the conjugate.
Mechanical loading induces the splice variant
Skeletal muscle expresses IGF-1Ec in response to mechanical stimulus and damage, which is where the name mechano-growth factor comes from.
E-domain liberation
Processing of the propeptide releases the C-terminal E-domain peptide, which is the portion sold under the MGF name rather than the full IGF-1 protein.
Satellite cell action
The E-domain is reported to act on satellite cells, the muscle progenitor population responsible for repair, promoting proliferation.
Proposed IGF-1 receptor independence
The E-domain is reported to act through a pathway distinct from the IGF-1 receptor, which would make it a separate signal rather than a variant route into IGF-1 signalling.
PEGylation as a pharmacokinetic modification
Polyethylene glycol conjugation increases hydrodynamic radius and shields against proteolysis, extending an otherwise very short half-life. Its effect on this specific peptide is unpublished.
IGF-1Ec and PEGylation Research Findings
No entry below used PEG-MGF. Each concerns either the unmodified E-domain peptide and its parent splice variant, or PEGylation applied to IGF-I, and each says which.
The human Ec peptide characterised as an active core
Work described the human Ec peptide as the active core of a progression growth factor with species-specific mode of action, which is the most direct characterisation of the peptide portion of this product.
In vitroIGF-1Ec role in musculoskeletal tissue examined
A review examined the role of IGF-1Ec in the myoskeletal system and in osteosarcoma pathophysiology, covering both the repair biology and the reason a proliferative signal warrants caution.
MechanisticEc and Eb peptides identified across tissues
Work identifying the IGF-1 processing products, human Ec and rodent Eb peptide, in various tissues established where these peptides actually occur rather than inferring it from muscle work alone.
In vitroMass spectrometric characterisation of biotechnologically produced MGF
Analytical work characterised a biotechnologically produced full-length mechano growth factor by mass spectrometry, in a doping control context. This is the closest thing to analytical literature on the material sold under this name.
In vitroPEGylated IGF-I taken into a first-in-human study
A first-in-man study of a novel PEGylated recombinant human IGF-I demonstrates that PEGylation of this protein family has been carried into humans, though with the full protein rather than the E-domain peptide.
Phase 1 trialBioresponsive release from a PEGylated IGF-I conjugate
Work on bioresponsive release of IGF-I from its PEGylated conjugate addressed how a PEG group can be attached so the active molecule is released, which is the central design question for any PEGylated peptide.
In vitroPEG-MGF Molecular Information
| Class | PEGylated peptide conjugate |
| Peptide Portion | C-terminal E-domain peptide of the IGF-1Ec splice variant |
| Peptide Molecular Weight | 2,867 g/mol before PEGylation, as stated on the product listing |
| Conjugate Molecular Weight | Not stated. It depends entirely on the PEG chain used |
| PEG Chain Length | Not disclosed on the product listing |
| Also Known As | Mechano-growth factor, MGF, IGF-1Ec E-domain |
| Parent Protein | IGF-1Ec, a splice variant of insulin-like growth factor 1 |
| Proposed Target Pathway | Distinct from the IGF-1 receptor, per the E-domain literature |
| CAS Number | Not stated on the product listing |
| Appearance | White lyophilised powder |
A Studied Peptide Plus a Studied Modification Is Not a Studied Molecule
The E-domain peptide has a real literature. PEGylation has a very large literature, including application to IGF-I specifically and into first-in-human study. Neither of those is a literature about PEG-MGF.
This matters because PEGylation is not inert. It changes not only half-life but also receptor access, tissue distribution and, frequently, potency: a PEG chain large enough to slow renal clearance is also large enough to interfere sterically with binding. That is why the field developed releasable and bioresponsive linkers, one of which is cited here, so the active molecule can detach from its PEG.
Whether the PEG on this product is a permanent conjugate or a releasable one is not stated, and neither is the chain length. Those two facts determine what the molecule does, and both are absent from the product information.
The Undisclosed PEG Is the Substantive Gap
For most compounds in this catalogue the identity question is whether the stated molecule is present. Here a large part of the molecule's mass and nearly all of its pharmacokinetic behaviour come from a component whose size and attachment chemistry are not specified anywhere.
A stated peptide mass of 2,867 daltons describes the peptide before conjugation. The conjugate's mass depends on the PEG, and PEG reagents are themselves polydisperse: they are distributions of chain lengths rather than single molecules, which is why PEGylated products show broad rather than sharp mass distributions.
The practical consequence is that a certificate for this product cannot report a single clean mass for the conjugate, and a certificate that does report one is either describing the unconjugated peptide or is not measuring what it claims.
Why the Osteosarcoma Reference Is Included
One of the references here concerns IGF-1Ec in osteosarcoma pathophysiology rather than in muscle repair. It is included deliberately rather than as an artefact of searching.
The E-domain's reported activity is promotion of progenitor cell proliferation. That is the desired effect in a repair context and it is the same property that makes the pathway of interest in a malignancy context. A signal that tells progenitor cells to divide does not distinguish between a torn muscle and a tumour, and the literature reflects both.
There are no human trials of the E-domain peptide for any purpose, no approval anywhere, and the compound appears in doping control literature, which is where the analytical characterisation cited here comes from.
Handling and Analytical Considerations
PEGylated peptides behave differently from unmodified ones in almost every analytical method. Reversed-phase retention shifts substantially, ultraviolet detection is unaffected by the PEG since it has no chromophore of its own, and size exclusion behaviour reflects the hydrodynamic radius rather than the true mass.
The polydispersity of PEG means a mass spectrum of a properly conjugated product shows a characteristic ladder of peaks separated by the repeat unit mass rather than a single species. A sharp single peak at the peptide mass indicates unconjugated peptide, which for this product would be a fundamental identity failure rather than a purity issue.
PEG-MGF Research FAQ
PEG-MGF in Summary
PEG-MGF is the C-terminal E-domain peptide of the IGF-1Ec splice variant conjugated to polyethylene glycol. The peptide is reported to act on muscle satellite cells through a pathway distinct from the IGF-1 receptor, and PEGylation addresses its very short half-life.
No published study has used the conjugate. The PEG chain length and attachment chemistry, which determine most of its behaviour, are not disclosed, and a correctly PEGylated product cannot show a single clean mass because PEG reagents are polydisperse.
Scientific References
Primary literature and public trial registries only. No supplier or retailer pages are cited.
No published study has used PEG-MGF. Searching PubMed for the PEGylated construct returns nothing. The references below cover the two things that can honestly be cited: the IGF-1Ec splice variant and its E-domain peptide, which is the peptide portion of this product, and PEGylation applied to IGF-I, which is the modification. Combining a studied peptide with a studied modification does not produce a studied molecule, and nothing here reports what the conjugate does.
- 1The human Ec peptide: the active core of a progression growth factor with species-specific mode of actionPapageorgiou E, Philippou A, Armakolas A, et al. · Hormones (Athens) · 2016
- 2The role of the IGF-1 Ec in myoskeletal system and osteosarcoma pathophysiologyArmakolas N, Armakolas A, Antonopoulos A, et al. · Critical Reviews in Oncology/Hematology · 2016
- 3Identification of the IGF-1 processing product human Ec/rodent Eb peptide in various tissuesVassilakos G, Philippou A, Koutsilieris M · Growth Hormone and IGF Research · 2017
- 4Mass spectrometric characterization of a biotechnologically produced full-length mechano growth factorThevis M, Thomas A, Schänzer W · Growth Hormone and IGF Research · 2014
- 5First-in-man study with a novel PEGylated recombinant human insulin-like growth factor-IKletzl H, Guenther A, et al. · Growth Hormone and IGF Research · 2017
- 6Bioresponsive release of insulin-like growth factor-I from its PEGylated conjugateBraun AC, Gutmann M, et al. · Journal of Controlled Release · 2018
Disclaimer
All articles and product information provided on this website are for informational and educational purposes only. The products offered on this website are furnished for in-vitro studies only. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease.
PEG-MGF 2mg: frequently asked questions
Answered from the product record and the certificate file. Volta does not answer questions about administration, dosing or protocols.
What is supplied in a 2 mg vial of PEG-MGF?
A sealed single-use vial containing 2 mg of PEG-MGF as a lyophilized powder. Soluble in bacteriostatic water. No diluent, syringe or other supply is included.
Is PEG-MGF supplied for human use?
No. For in-vitro laboratory research by qualified professionals only. Not for human or animal administration. Not a drug, food, cosmetic or dietary supplement. Not intended to diagnose, treat, cure, mitigate or prevent any disease. Volta does not provide dosing, administration or protocol guidance for any material listed.
What purity is this PEG-MGF released to?
>99% by HPLC. That figure is a release specification, a threshold Volta sets for every batch, and it is not the same kind of statement as a purity measured by a named laboratory for a named lot.
Is there a certificate of analysis for this PEG-MGF vial?
A batch-specific Certificate of Analysis is available for this product on request. It is not published on the site yet: the batch history on the quality page lists the certificates already published, and this vial is covered by the release specification until its own is added there.
How is PEG-MGF identified?
molecular weight 2,867 g/mol (peptide portion, before PEGylation). Those identifiers are what an incoming-goods check compares a certificate against, and they are stated here so the comparison can be made before ordering.
How should PEG-MGF be stored before reconstitution?
Store lyophilized peptide at -20°C in a dry, dark environment. Reconstitute in bacteriostatic water. Once reconstituted, store at 2-8°C and use within 30 days. Avoid repeated freeze-thaw cycles. Lyophilized powder is stable at room temperature for shipping and short-term storage.
Where does this ship from?
British Columbia, Canada. Canadian orders are domestic, so they clear no customs and pay no import duty. International orders ship from the same facility.
Explore Research
Peptide Tools
More from the research catalogue
Every compound below has its own specification, batch number and certificate page, whether or not a vial is in stock today. Supplied for laboratory research use only.